sulfasalazine has been researched along with Glioma in 21 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas." | 9.14 | Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. ( Albert, A; Artesi, M; Bours, V; Bredel, M; Califice, S; Deprez, M; Martin, DH; Nguyen-Khac, MT; Robe, PA; Vanbelle, S, 2009) |
| " A total of twenty patients with progressive malignant glioma despite surgery, radiation therapy and a first line of chemotherapy will be recruited and assigned to four dosage regimen of Sulfasalazine." | 9.12 | A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. ( Albert, A; Bours, V; Chariot, A; Deprez, M; Martin, D; Robe, PA, 2006) |
| "Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas." | 7.88 | Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. ( Akashi, K; Baba, E; Hirata, Y; Kamenori, S; Mitsuishi, Y; Nagano, O; Okazaki, S; Sampetrean, O; Saya, H; Shintani, S; Suina, K; Takahashi, F; Takahashi, K; Tsuchihashi, K; Yamasaki, J, 2018) |
| " Glioma cells may synthetize the antioxidant glutathione by importing cystine through a cystine/glutamate antiporter, which is inhibited by sulfasalazine (SAS)." | 7.85 | Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells. ( Castilho, RF; de Melo, DR; Facchini, G; Ferreira, CV; Ignarro, RS; Pelizzaro-Rocha, KJ; Rogerio, F, 2017) |
| " Food and Drug Administration and EMA-approved xCT inhibitor, sulfasalazine (SAS) in gliomas." | 7.83 | Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. ( Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T, 2016) |
| " Celastrol, isolated from a Chinese medicinal herb, is a novel heat shock protein 90 (Hsp90) inhibitor with potent anticancer activity against glioma in vitro and in vivo." | 7.76 | Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. ( Alvarado, O; Blower, PE; Gout, PW; Huang, Y; Pham, AN; Ravula, R, 2010) |
| "The efficacy of HSV-TK/ganciclovir-based gene therapy on malignant gliomas largely relies on the amplitude of the bystander effect." | 7.74 | Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. ( Bours, V; Ernst-Gengoux, P; Jolois, O; Lambert, F; Lechanteur, C; Nguyen-Khac, MT; Robe, PA; Rogister, B, 2007) |
| "Sulfasalazine (SAS) is a classic inhibitor of NF-κB." | 5.42 | p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells. ( Kang, J; Li, X; Li, Y; Liu, F; Su, J; Sun, L; Xia, M; Xu, Y, 2015) |
| "Celecoxib has been utilized with success in the treatment of several types of cancer, including gliomas." | 5.42 | Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. ( Winfield, LL; Yerokun, T, 2015) |
| "Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas." | 5.14 | Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. ( Albert, A; Artesi, M; Bours, V; Bredel, M; Califice, S; Deprez, M; Martin, DH; Nguyen-Khac, MT; Robe, PA; Vanbelle, S, 2009) |
| " A total of twenty patients with progressive malignant glioma despite surgery, radiation therapy and a first line of chemotherapy will be recruited and assigned to four dosage regimen of Sulfasalazine." | 5.12 | A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. ( Albert, A; Bours, V; Chariot, A; Deprez, M; Martin, D; Robe, PA, 2006) |
| "Autocrine and paracrine factors, including glutamate and epidermal growth factor (EGF), are potent inducers of brain tumor cell invasion, a pathological hallmark of malignant gliomas." | 3.88 | Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. ( Akashi, K; Baba, E; Hirata, Y; Kamenori, S; Mitsuishi, Y; Nagano, O; Okazaki, S; Sampetrean, O; Saya, H; Shintani, S; Suina, K; Takahashi, F; Takahashi, K; Tsuchihashi, K; Yamasaki, J, 2018) |
| " Glioma cells may synthetize the antioxidant glutathione by importing cystine through a cystine/glutamate antiporter, which is inhibited by sulfasalazine (SAS)." | 3.85 | Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells. ( Castilho, RF; de Melo, DR; Facchini, G; Ferreira, CV; Ignarro, RS; Pelizzaro-Rocha, KJ; Rogerio, F, 2017) |
| " Food and Drug Administration and EMA-approved xCT inhibitor, sulfasalazine (SAS) in gliomas." | 3.83 | Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. ( Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T, 2016) |
| " Celastrol, isolated from a Chinese medicinal herb, is a novel heat shock protein 90 (Hsp90) inhibitor with potent anticancer activity against glioma in vitro and in vivo." | 3.76 | Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. ( Alvarado, O; Blower, PE; Gout, PW; Huang, Y; Pham, AN; Ravula, R, 2010) |
| " Sulfasalazine which is used clinically to treat Crohn's disease has emerged as a potential inhibitor of NF-kappaB and has shown promising results in two pre-clinical studies to target primary brain tumors, gliomas." | 3.75 | Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. ( Chung, WJ; Sontheimer, H, 2009) |
| "The efficacy of HSV-TK/ganciclovir-based gene therapy on malignant gliomas largely relies on the amplitude of the bystander effect." | 3.74 | Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. ( Bours, V; Ernst-Gengoux, P; Jolois, O; Lambert, F; Lechanteur, C; Nguyen-Khac, MT; Robe, PA; Rogister, B, 2007) |
| "Gliomas are primary brain tumors with still poor prognosis for the patients despite a combination of cytoreduction via surgery followed by a radio-chemotherapy." | 1.62 | Chemical hybridization of sulfasalazine and dihydroartemisinin promotes brain tumor cell death. ( Ackermann, A; Buchfelder, M; Çapcı, A; Savaskan, N; Tsogoeva, SB, 2021) |
| "Sulfasalazine (SAS) is a classic inhibitor of NF-κB." | 1.42 | p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells. ( Kang, J; Li, X; Li, Y; Liu, F; Su, J; Sun, L; Xia, M; Xu, Y, 2015) |
| "Celecoxib has been utilized with success in the treatment of several types of cancer, including gliomas." | 1.42 | Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. ( Winfield, LL; Yerokun, T, 2015) |
| "Control of seizures in patients with gliomas is an essential component of clinical management; therefore, understanding the origin of seizures is vital." | 1.38 | Human glioma cells induce hyperexcitability in cortical networks. ( Buckingham, SC; Campbell, SL; Sontheimer, H, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Ackermann, A | 1 |
| Çapcı, A | 1 |
| Buchfelder, M | 2 |
| Tsogoeva, SB | 1 |
| Savaskan, N | 2 |
| Cong, Z | 1 |
| Yuan, F | 1 |
| Wang, H | 1 |
| Cai, X | 1 |
| Zhu, J | 1 |
| Tang, T | 1 |
| Zhang, L | 1 |
| Han, Y | 1 |
| Ma, C | 1 |
| Haryu, S | 1 |
| Saito, R | 1 |
| Jia, W | 1 |
| Shoji, T | 1 |
| Mano, Y | 1 |
| Sato, A | 1 |
| Kanamori, M | 1 |
| Sonoda, Y | 1 |
| Sampetrean, O | 3 |
| Saya, H | 3 |
| Tominaga, T | 1 |
| Suina, K | 1 |
| Tsuchihashi, K | 2 |
| Yamasaki, J | 1 |
| Kamenori, S | 1 |
| Shintani, S | 1 |
| Hirata, Y | 1 |
| Okazaki, S | 2 |
| Baba, E | 2 |
| Akashi, K | 2 |
| Mitsuishi, Y | 1 |
| Takahashi, F | 1 |
| Takahashi, K | 1 |
| Nagano, O | 2 |
| Blecic, S | 1 |
| Rynkowski, M | 1 |
| De Witte, O | 1 |
| Lefranc, F | 1 |
| Su, J | 1 |
| Liu, F | 1 |
| Xia, M | 1 |
| Xu, Y | 1 |
| Li, X | 1 |
| Kang, J | 1 |
| Li, Y | 1 |
| Sun, L | 1 |
| Thomas, AG | 1 |
| Sattler, R | 1 |
| Tendyke, K | 1 |
| Loiacono, KA | 1 |
| Hansen, H | 1 |
| Sahni, V | 1 |
| Hashizume, Y | 1 |
| Rojas, C | 1 |
| Slusher, BS | 1 |
| Yerokun, T | 1 |
| Winfield, LL | 1 |
| Ohmura, M | 1 |
| Ishikawa, M | 1 |
| Onishi, N | 1 |
| Wakimoto, H | 1 |
| Yoshikawa, M | 1 |
| Seishima, R | 1 |
| Iwasaki, Y | 1 |
| Morikawa, T | 1 |
| Abe, S | 1 |
| Takao, A | 1 |
| Shimizu, M | 1 |
| Masuko, T | 1 |
| Nagane, M | 1 |
| Furnari, FB | 1 |
| Akiyama, T | 1 |
| Suematsu, M | 1 |
| Sehm, T | 1 |
| Fan, Z | 1 |
| Ghoochani, A | 1 |
| Rauh, M | 1 |
| Engelhorn, T | 1 |
| Minakaki, G | 1 |
| Dörfler, A | 1 |
| Klucken, J | 1 |
| Eyüpoglu, IY | 1 |
| Ignarro, RS | 1 |
| Facchini, G | 1 |
| de Melo, DR | 1 |
| Pelizzaro-Rocha, KJ | 1 |
| Ferreira, CV | 1 |
| Castilho, RF | 1 |
| Rogerio, F | 1 |
| Nawashiro, H | 1 |
| Chung, WJ | 1 |
| Sontheimer, H | 4 |
| Robe, PA | 3 |
| Martin, DH | 1 |
| Nguyen-Khac, MT | 2 |
| Artesi, M | 1 |
| Deprez, M | 2 |
| Albert, A | 2 |
| Vanbelle, S | 1 |
| Califice, S | 1 |
| Bredel, M | 1 |
| Bours, V | 3 |
| Pham, AN | 1 |
| Blower, PE | 1 |
| Alvarado, O | 1 |
| Ravula, R | 1 |
| Gout, PW | 1 |
| Huang, Y | 1 |
| Buckingham, SC | 2 |
| Campbell, SL | 2 |
| Haas, BR | 1 |
| Montana, V | 1 |
| Robel, S | 1 |
| Ogunrinu, T | 1 |
| Bridges, RJ | 1 |
| Hermisson, M | 1 |
| Weller, M | 1 |
| Martin, D | 1 |
| Chariot, A | 1 |
| Lambert, F | 1 |
| Lechanteur, C | 1 |
| Jolois, O | 1 |
| Ernst-Gengoux, P | 1 |
| Rogister, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial Combining Sulfasalazine and Gamma Knife Radiosurgery for Recurrent Glioblastoma[NCT04205357] | Phase 1 | 24 participants (Actual) | Interventional | 2020-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for sulfasalazine and Glioma
| Article | Year |
|---|---|
[Glutamate and malignant gliomas, from epilepsia to biological aggressiveness: therapeutic implications].
Topics: Benzodiazepines; Brain Neoplasms; Cell Death; Cell Movement; Cell Proliferation; Dizocilpine Maleate | 2013 |
2 trials available for sulfasalazine and Glioma
| Article | Year |
|---|---|
Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.
Topics: Adult; Disease Progression; Early Termination of Clinical Trials; Female; Glioma; Humans; Male; Midd | 2009 |
A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668].
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Brain Neoplasms; Disease | 2006 |
18 other studies available for sulfasalazine and Glioma
| Article | Year |
|---|---|
Chemical hybridization of sulfasalazine and dihydroartemisinin promotes brain tumor cell death.
Topics: Antineoplastic Agents; Artemisinins; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Glio | 2021 |
BTB domain and CNC homolog 1 promotes glioma invasion mainly through regulating extracellular matrix and increases ferroptosis sensitivity.
Topics: Basic-Leucine Zipper Transcription Factors; BTB-POZ Domain; Extracellular Matrix; Ferroptosis; Gliom | 2022 |
Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Brain Chemistry; | 2018 |
Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prol | 2018 |
p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Autophagy; Cell Line, Tumor; Glioma; Humans; NF-kap | 2015 |
High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells.
Topics: Amino Acid Transport System y+; Benzoates; Brain Neoplasms; Cell Line, Tumor; Cystine; Databases, Ch | 2015 |
Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Celecoxib; Cell Lin | 2015 |
The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-).
Topics: Amino Acid Transport System y+; Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Membrane; Ce | 2016 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Characteristics of sulfasalazine-induced cytotoxicity in C6 rat glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioma; Glu | 2017 |
Idiopathic intracranial hypertension associated with sulphasalazine treatment.
Topics: Amino Acid Transport System y+; Anti-Inflammatory Agents, Non-Steroidal; Brain Neoplasms; Glioma; Hu | 2008 |
Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Li | 2009 |
Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferati | 2010 |
Glutamate release by primary brain tumors induces epileptic activity.
Topics: Amino Acid Transport System y+; Analysis of Variance; Animals; Brain Neoplasms; Cell Transplantation | 2011 |
Sulfasalazine for brain cancer fits.
Topics: Amino Acid Transport System y+; Animals; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Ep | 2012 |
Human glioma cells induce hyperexcitability in cortical networks.
Topics: Action Potentials; Animals; Brain; Brain Neoplasms; Disease Models, Animal; Electrophysiology; Femal | 2012 |
NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Nu | 2003 |
Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas.
Topics: Bystander Effect; Cell Line, Tumor; Cell Survival; Ganciclovir; Genetic Therapy; Glioma; Humans; Sim | 2007 |